Group 1 - The pharmaceutical sector is experiencing significant activity, with notable stocks such as Sanofi and Yipinhong reaching their daily limit up of 19.99%, and others like Shutaishen rising over 9% [1] - Major pharmaceutical companies reported impressive Q1 earnings, with BeiGene achieving a revenue of 8.048 billion yuan, a 50.2% increase from the previous year, and a significant reduction in net losses [1] - Innovent Biologics reported a revenue of 381 million yuan for Q1, marking a 129.92% year-on-year growth, and a net profit of 18 million yuan, up 112.62% year-on-year, indicating a turnaround to profitability [1] Group 2 - Wanlian Securities forecasts a performance divergence in the pharmaceutical sub-sectors for Q1 2024 and 2025, with strong revenue and profit growth expected in medical R&D outsourcing, hospitals, and other biological products [2] - The chemical pharmaceutical sector is gaining market attention, focusing on innovation-driven growth, domestic production, and policy immunity [2] - China Galaxy notes that the pharmaceutical sector has undergone a long adjustment period, resulting in low valuations and underweight public holdings, with expectations for policy support and market demand recovery to drive growth [2]

Core Viewpoint - The China Securities Index of Hong Kong and Shenzhen Technology Leaders (SHS Technology Leaders) shows mixed performance in the A-share market, with a slight increase of 0.04% on the latest trading day, reflecting a 6.87% increase over the past month and a 9.58% increase year-to-date [1][2]. Group 1: Index Performance - The SHS Technology Leaders Index closed at 2185.36 points with a trading volume of 76.457 billion yuan [1]. - Over the last three months, the index has decreased by 6.49% [1]. - The index was established on November 14, 2014, with a base point of 1000.0 [1]. Group 2: Index Composition - The index comprises 50 large-cap technology companies with significant market share and R&D investment [1]. - The top ten holdings in the index include Alibaba-W (12.91%), Tencent Holdings (11.03%), Xiaomi Group-W (10.43%), Meituan-W (6.96%), and SMIC (3.48%) [1]. - The market distribution of the index holdings shows that the Hong Kong Stock Exchange accounts for 54.65%, Shenzhen Stock Exchange for 29.20%, and Shanghai Stock Exchange for 16.15% [1]. Group 3: Sector Allocation - The sector allocation of the index includes Information Technology (45.15%), Consumer Discretionary (19.87%), Healthcare (17.49%), Communication Services (12.98%), and Industrials (4.51%) [2]. - The index samples are adjusted biannually, with adjustments occurring on the next trading day after the second Friday of June and December [2]. - Public funds tracking the SHS Technology Leaders include various funds from Penghua, GF, and Huatai-PineBridge [2].

| 代码 名称 | 现价 | 涨跌 涨幅↓ | | --- | --- | --- | | 300255 常山药业 | 13.78 | +2.30 +20.03% | | 300363 博腾股份 | 29.64 | +4.18 +16.42% | | 002038 双鹭药业 | 11.74 | +1.07 +10.03% | | 000813 德展健康 | 4.54 | +0.41 +9.93% | | 688166 博瑞医药 | 29.39 | +2.29 +8.45% | | 688076 诺泰牛物 | 39.66 | +2.97 +8.09% | | 301393 吴帆生物 | 78.79 | +4.59 +6.19% | | 600721 百花医药 | 8.47 | +0.47 +5.88% | | 605116 奥锐特 | 23.01 | +1.20 +5.50% | | 301092 争光股份 | 32.62 | +1.24 =+1.95% | 自9月8日以来，医药各细分板块进入稳步上行阶段，其中涨幅最大的减肥药板块，14个交易日内涨超 22%。 今日，医药板块情绪格外高涨。 A股方面，CRO概念 ...

Group 1 - Ningde Times has set the H-share offering price at HKD 263.00 per share, with an additional issuance of 17,684,100 shares, representing approximately 15.0% of the total shares available for subscription [1] - The additional shares will be allocated based on an initial ratio of 7.5% for the Hong Kong public offering and 92.5% for the international offering [1] - The H-shares are expected to commence trading on the Hong Kong Stock Exchange on May 20, 2025, at 9:00 AM [1] Group 2 - Moody's has downgraded the U.S. credit rating from AAA to AA1, impacting market sentiment [2] - Major U.S. stock indices showed positive performance, with the Dow Jones up 331.99 points (0.78%) and the S&P 500 up 41.45 points (0.70%) [2] - The Nasdaq China Golden Dragon Index rose by 4.56% over the week, indicating a positive trend for Chinese concept stocks [2] Group 3 - The Hang Seng Index Company announced the quarterly review results, increasing the number of constituent stocks from 83 to 85, with BYD included in the Hang Seng Tech Index [3] Group 4 - The Central Committee of the Communist Party and the State Council have mandated that government procurement of vehicles should prioritize domestic and new energy vehicles [4] Group 5 - The revised regulations prohibit high-end dishes and alcohol in official work meals, emphasizing cost control in government receptions [5] Group 6 - The Financial Secretary of Hong Kong stated that global funds are increasingly flowing towards leading innovative technology companies and future industries [6] Group 7 - The China Securities Regulatory Commission encourages private equity funds to participate in mergers and acquisitions of listed companies, with adjustments to lock-up periods for investments [7][8] Group 8 - WuXi AppTec's subsidiary, Hanbang Technology, was listed on the Shanghai Stock Exchange on May 16, 2025 [9] Group 9 - Weichai Power expects significant growth in sales of its M-series large-bore engines and data center products, driven by strong industry demand [10] Group 10 - Shandong Xinhua Pharmaceutical is the largest producer of ibuprofen raw materials in China, with an annual production capacity exceeding 8,000 tons, accounting for 40% of global capacity [11] - The company holds a 62.66% market share in China and exports 60% of its total production, primarily to high-end markets in Europe and the U.S. [11]

本海外監管公告乃由本公司根據香港聯合交易所有限公司證券上市規則第 13.10B條作出。 茲載列本公司在上海證券交易所網站刊登的以下資料中文全文，僅供參閱。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因依賴該等內容而引致之任何損失承擔任何責任。 WUXI APPTEC CO., LTD. * 無錫藥明康德新藥開發股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2359） 海外監管公告 * 僅供識別 证券代码：603259 证券简称：药明康德 公告编号：临 2025-038 承董事會命 無錫藥明康德新藥開發股份有限公司 董事長 李革博士 截至本公告日期，本公司董事會包括執行董事李革博士、陳民章博士、胡正國先生、楊青博士及 張朝暉先生；非執行董事童小幪先生及吳亦兵博士；以及獨立非執行董事盧韶華女士、俞衛博士、 張新博士、詹智玲女士及冷雪松先生。 无锡药明康德新药开发股份有限公司 香港，2025年5月18日 三、相关股权的会计处理方式 根据《企业会计准则第 22 号—金融工具 ...

Group 1 - The core point of the announcement is that Wuxi AppTec's subsidiary, Jiangsu Hanbang Technology Co., Ltd., was listed on the Shanghai Stock Exchange on May 16, 2025 [1] - Wuxi AppTec indirectly holds 5,313,131 shares of Hanbang Technology, representing 6.04% of its total share capital after the IPO [1] - The investment is classified as a financial asset measured at fair value with changes recognized in profit or loss, and it is reported under "other non-current financial assets" [1] Group 2 - The fair value of this investment is less than 0.5% of Wuxi AppTec's audited net assets attributable to shareholders for the year 2024, and it does not have a significant impact on the profit for the year 2025 [1] - The company anticipates no significant changes in the accounting treatment of this investment in the future [2] - The fair value of the investment may fluctuate due to stock market price changes, leading to uncertain impacts on the company's performance [2]

证券代码：603259 证券简称：药明康德 公告编号：临 2025-038 无锡药明康德新药开发股份有限公司 关于参股公司股票上市的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、参股公司上市情况概述 无锡药明康德新药开发股份有限公司（以下简称"本公司"）参股公司江苏 汉邦科技股份有限公司（以下简称"汉邦科技"）于 2025 年 5 月 16 日在上海 证券交易所上市。 二、持股情况 本公司间接持有汉邦科技的股份数量为 5,313,131 股，占其首次公开发行完 成后总股本的 6.04%（以下简称"本项投资"）。 三、相关股权的会计处理方式 根据《企业会计准则第 22 号—金融工具确认和计量》等一系列金融工具相 关会计准则，本公司将本项投资划分为"以公允价值计量且其变动计入当期损 益的金融资产"，并列报在"其他非流动金融资产"中。截止本公告日，本项 投资的公允价值占本公司2024年度经审计归属于上市公司股东的净资产的比例 小于 0.5%，且对 2025 年度当期利润无重大影响。 未来本公司对本项投资的会计处理方法预计 ...

JohnV.Oyler（欧雷强） ，1968年出生，百济神州联合创始人，自2010年起一直担任公司执行董事、董事会 主席兼首席执行官。于1990年获得麻省理工学院的理学学士学位，于1996年获得斯坦福大学的工商管理硕 士学位。欧雷强以管理顾问职务在麦肯锡公司（McKinsey&Company）开始其职业生涯。1997年至1998 年，欧雷强担任GentaIncorporated联席首席执行官，该公司为一家在纳斯达克交易所上市的以肿瘤为重点的 生物制药企业。1998年至2002年，欧雷强创立Telephia,Inc.并担任总裁，该公司于2007年被尼尔森公司 （The Nielsen Company）收购。2002年至2004年，欧雷强担任Galenea Corp的首席执行官，该公司为一家致 力于开发新的中枢神经系统疾病治疗方法的生物制药企业。2005年至2009年，欧雷强担任BioDuro,LLC的总 裁兼首席执行官，该公司为一家药品开发外包公司，后被Pharmaceutical Product Development Inc.收购。 2019年，欧雷强正式入选生物技术产业协会（BIO）董事会及其卫生部门理事 ...

Group 1 - The core viewpoint of the articles highlights the performance and valuation of WuXi AppTec, with a closing price of 61.03 yuan and a rolling PE ratio of 15.77, marking a new low in 26 days [1] - The total market capitalization of WuXi AppTec is reported at 176.254 billion yuan, ranking 17th in the medical services industry, which has an average PE ratio of 38.39 [1][2] - As of the first quarter of 2025, 385 institutions hold shares in WuXi AppTec, with a total shareholding of 1,109.7928 million shares valued at 74.711 billion yuan [1] Group 2 - WuXi AppTec's main business involves providing integrated, end-to-end drug research and development services for the global pharmaceutical and life sciences industry, with key products in chemical, testing, and biological services [1] - The latest financial results for the first quarter of 2025 show that the company achieved operating revenue of 9.655 billion yuan, a year-on-year increase of 20.96%, and a net profit of 3.672 billion yuan, reflecting a year-on-year growth of 89.06% [1] - The sales gross margin for WuXi AppTec stands at 42.26% [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因依賴該等內容而引致之任何損失承擔任何責任。 WUXI APPTEC CO., LTD. * 無錫藥明康德新藥開發股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2359） 海外監管公告 本海外監管公告乃由本公司根據香港聯合交易所有限公司證券上市規則第 13.10B條作出。 茲載列本公司在上海證券交易所網站刊登的以下資料中文全文，僅供參閱。 承董事會命 無錫藥明康德新藥開發股份有限公司 董事長 李革博士 香港，2025年5月14日 截至本公告日期，本公司董事會包括執行董事李革博士、陳民章博士、胡正國先生、楊青博士及 張朝暉先生；非執行董事童小幪先生及吳亦兵博士；以及獨立非執行董事盧韶華女士、俞衛博士、 張新博士、詹智玲女士及冷雪松先生。 * 僅供識別 证券代码：603259 证券简称：药明康德 公告编号：临 2025-036 无锡药明康德新药开发股份有限公司2024年度及 2025 年回报股东特别分红 A 股权益分派实施公告 ...